| 1 |
Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies |
|
| | Wei-Xiang Qi,Feng Lin,Ai-Na He,Li-Na Tang,Zan Shen,Yang Yao | | | Current Medical Research and Opinion. 2013; 29(9): 1067 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Antiresorptive treatment options and bone health in cancer patients—safety profiles and clinical considerations |
|
| | Peyman Hadji,Matti Aapro,Luis Costa,Michael Gnant | | | Cancer Treatment Reviews. 2012; 38(6): 815 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment |
|
| | Draupadi B. Talreja | | | Journal of Drug Assessment. 2012; 1: 30 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Risk Factors Contributing to the Development of Hypocalcemia after Zoledronic Acid Administration in Patients with Bone Metastases of Solid Tumor |
|
| | Miho Hanamura, Takuya Iwamoto, Norihito Soga, Yoshiki Sugimura, Masahiro Okuda | | | Biological & Pharmaceutical Bulletin. 2010; 33(4): 721 | | | [HTML Full text] [Google Scholar] [DOI] | | | 5 |
Current awareness: Pharmacoepidemiology and drug safety |
|
| | | | | Pharmacoepidemiology and Drug Safety. 2009; 18(1): i | | | [HTML Full text] [Google Scholar] [DOI] | |
|
